Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 9/20 | 0.69 |
| ▸ | AKR1A1 | P14550 | 5/20 | 0.52 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671705 | 0.92 | AKR1B1 (0.61) | AKR1B1AKR1A1AKR1B10 | |
| SCHEMBL10929003 | 0.91 | AKR1B1 (0.60) | AKR1B1AKR1A1AKR1B10CYP1A2MAPT | |
| SCHEMBL21844215 | 0.87 | AKR1B1 (0.62) | AKR1B1AKR1A1AKR1B10 | |
| SCHEMBL9672965 | 0.87 | AKR1B1 (0.56) | AKR1B1AKR1A1AKR1B10CYP1A2MAPT | |
| SCHEMBL9673456 | 0.85 | AKR1B1 (0.57) | AKR1B1AKR1A1AKR1B10CYP1A2MAPT | |
| SCHEMBL10345515 | 0.83 | AKR1B1 (0.55) | AKR1B1AKR1A1AKR1B10 | |
| SCHEMBL10930198 | 0.83 | AKR1B1 (0.55) | AKR1B1AKR1A1AKR1B10 | |
| SCHEMBL10975155 | 0.82 | AKR1B1 (0.51) | AKR1B1AKR1A1AKR1B10MAPT | |
| SCHEMBL10929989 | 0.81 | AKR1B1 (0.56) | AKR1B1AKR1A1AKR1B10CYP1A2MAPT | |
| SCHEMBL9673557 | 0.74 | AKR1B1 (0.45) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4609663-A | Aldose reductase inhibitors useful in glaucoma therapy | ALCON LABORATORIES, INC. (US) | 1986-09-02 | — | — | US | claimed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| EP-0306525-A4 | USE OF ALDOSE REDUCTASE INHIBITORS TO ENHANCE INSULIN SENSITIVITY IN DIABETES MELLITUS | — | 1991-04-24 | — | — | EP | disclosed |
| EP-0258476-B1 | ALDOSE REDUCTASE INHIBITORS USEFUL IN GLAUCOMA THERAPY | ALCON LABORATORIES, INC. (US) | 1990-04-25 | — | — | EP | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0306525-A1 | USE OF ALDOSE REDUCTASE INHIBITORS TO ENHANCE INSULIN SENSITIVITY IN DIABETES MELLITUS | ALCON LABORATORIES, INC. (US) | 1989-03-15 | — | — | EP | disclosed |
| WO-1988006887-A1 | USE OF ALDOSE REDUCTASE INHIBITORS TO ENHANCE INSULIN SENSITIVITY IN DIABETES MELLITUS | ALCON LABORATORIES, INC. (US) | 1988-09-22 | — | — | WO | disclosed |
| US-4717725-A | SPIROCYCLIC AROMATIC IMIDES | ALCON LABORATORIES, INC. (US) | 1988-01-05 | — | — | US | disclosed |
| US-4609663-A | Aldose reductase inhibitors useful in glaucoma therapy | ALCON LABORATORIES, INC. (US) | 1986-09-02 | — | — | US | disclosed |
| US-4600717-A | Aldose reductase inhibitors useful in ophthalmic wound healing | ALCON LABORATORIES, INC. (US) | 1986-07-15 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |